BAJAJ BROKING

Notification
No new Notification messages
One Mobikwik Systems IPO is Open!
Apply for the One Mobikwik Systems IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
kilitch drugs india ltd stock

KILITCH DRUGS INDIA LTD Share Price

326.5 1.70 (0.52%)
Dec 11 2024 03:29 PM Pharmaceuticals NSE: KILITCH

KILITCH DRUGS INDIA LTD Share Price Update

As of the latest trading session, KILITCH DRUGS INDIA LTD share price is currently at 326.5, which is up by 1.70 from its previous closing. Today, the stock has fluctuated between 324.05 and 332.00. Over the past year, KILITCH DRUGS INDIA LTD has achieved a return of -5.20 %. In the last month alone, the return has been 7.63 %. Read More...

KILITCH DRUGS INDIA LTD Performance

Day Range

Low324.05 High332.00
328.70

52 Week Range

Low 300.00 High 470.00
328.70

KILITCH DRUGS INDIA LTD Share Price

19937

524500

KILITCH

img img img img
No Data Available

Open Price

324.50

Prev. Close

324.80

Volume (Shares)

3497.00

Total traded value

11.49

Upper Circuit

389.75

Lower Circuit

259.85

Note: The current prices & values are delayed, Login to your account for live updates.

KILITCH DRUGS INDIA LTD Fundamentals


(Standalone)

Market Cap (Cr) 525.08
PE Ratio (TTM) 23.87
Book Value / Share 147.27
Beta 0.68
ROE 8.39%
EPS (TTM) 13.71
Dividend Yield 0.00%
Net Profit Qtr (Cr) 8.85

KILITCH DRUGS INDIA LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 45.35
Operating Expense 40.58
Net Profit 8.85
Net Profit Margin (%) 19.51
Earnings Per Share (EPS) 5.50
EBITDA 11.40
Effective Tax Rate (%) 16.35
Particulars JUN 2024 (Values in Cr)
Revenue 33.42
Operating Expense 31.04
Net Profit 4.05
Net Profit Margin (%) 12.11
Earnings Per Share (EPS) 2.52
EBITDA 6.43
Effective Tax Rate (%) 27.54
Particulars MAR 2024 (Values in Cr)
Revenue 39.14
Operating Expense 34.76
Net Profit 3.64
Net Profit Margin (%) 9.29
Earnings Per Share (EPS) 2.26
EBITDA 6.11
Effective Tax Rate (%) 30.79
Particulars DEC 2023 (Values in Cr)
Revenue 29.77
Operating Expense 26.57
Net Profit 5.50
Net Profit Margin (%) 18.47
Earnings Per Share (EPS) 3.48
EBITDA 7.41
Effective Tax Rate (%) 16.41
Particulars SEP 2023 (Values in Cr)
Revenue 31.57
Operating Expense 26.56
Net Profit 4.24
Net Profit Margin (%) 13.43
Earnings Per Share (EPS) 2.60
EBITDA 6.76
Effective Tax Rate (%) 28.49
Particulars MAR 2024 (Values in Cr)
Revenue 131.60
Operating Expense 114.44
Net Profit 17.57
Net Profit Margin (%) 13.35
Earnings Per Share (EPS) 11.03
EBITDA 26.50
Effective Tax Rate (%) 24.75
Particulars MAR 2023 (Values in Cr)
Revenue 117.78
Operating Expense 102.94
Net Profit 15.72
Net Profit Margin (%) 13.34
Earnings Per Share (EPS) 10.09
EBITDA 21.77
Effective Tax Rate (%) 19.17
Particulars MAR 2022 (Values in Cr)
Revenue 105.16
Operating Expense 95.78
Net Profit 10.53
Net Profit Margin (%) 10.01
Earnings Per Share (EPS) 6.76
EBITDA 15.55
Effective Tax Rate (%) 24.40
Particulars MAR 2021 (Values in Cr)
Revenue 70.02
Operating Expense 66.70
Net Profit 6.16
Net Profit Margin (%) 8.79
Earnings Per Share (EPS) 3.98
EBITDA 9.40
Effective Tax Rate (%) 17.97
Particulars MAR 2020 (Values in Cr)
Revenue 60.77
Operating Expense 61.26
Net Profit 4.46
Net Profit Margin (%) 7.33
Earnings Per Share (EPS) 2.89
EBITDA 7.09
Effective Tax Rate (%) 14.75
Particulars MAR 2024 (Values in Cr)
Book Value / Share 109.62
ROE % 8.28
ROCE % 13.30
Total Debt to Total Equity 0.16
EBITDA Margin 18.62
Particulars MAR 2023 (Values in Cr)
Book Value / Share 94.08
ROE % 5.70
ROCE % 10.24
Total Debt to Total Equity 0.15
EBITDA Margin 14.79
Particulars MAR 2022 (Values in Cr)
Book Value / Share 89.26
ROE % 4.03
ROCE % 6.34
Total Debt to Total Equity 0.13
EBITDA Margin 10.55
Particulars MAR 2021 (Values in Cr)
Book Value / Share 82.05
ROE % 2.41
ROCE % 3.51
Total Debt to Total Equity 0.11
EBITDA Margin 9.90
Particulars MAR 2020 (Values in Cr)
Book Value / Share 76.62
ROE % -0.18
ROCE % 0.56
Total Debt to Total Equity 0.09
EBITDA Margin 5.12
Particulars MAR 2024 (Values in Cr)
Book Value / Share 138.61
ROE % 8.39
ROCE % 10.74
Total Debt to Total Equity 0.13
EBITDA Margin 20.23
Particulars MAR 2023 (Values in Cr)
Book Value / Share 122.53
ROE % 8.41
ROCE % 9.89
Total Debt to Total Equity 0.11
EBITDA Margin 18.63
Particulars MAR 2022 (Values in Cr)
Book Value / Share 112.65
ROE % 6.18
ROCE % 7.82
Total Debt to Total Equity 0.10
EBITDA Margin 14.92
Particulars MAR 2021 (Values in Cr)
Book Value / Share 105.16
ROE % 3.32
ROCE % 4.20
Total Debt to Total Equity 0.09
EBITDA Margin 11.90
Particulars MAR 2020 (Values in Cr)
Book Value / Share 98.25
ROE % 1.92
ROCE % 2.67
Total Debt to Total Equity 0.07
EBITDA Margin 9.03
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 19.64
Total Assets 240.06
Total Liabilities 240.06
Total Equity 175.67
Share Outstanding 16082319
Price to Book Ratio 2.81
Return on Assets (%) 6.08
Return on Capital (%) 7.04
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 19.97
Total Assets 219.52
Total Liabilities 219.52
Total Equity 150.57
Share Outstanding 15582319
Price to Book Ratio 1.14
Return on Assets (%) 4.75
Return on Capital (%) 6.05
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 10.06
Total Assets 209.84
Total Liabilities 209.84
Total Equity 140.29
Share Outstanding 15582319
Price to Book Ratio 1.49
Return on Assets (%) 3.51
Return on Capital (%) 4.58
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 12.50
Total Assets 203.17
Total Liabilities 203.17
Total Equity 129.47
Share Outstanding 15494544
Price to Book Ratio 0.77
Return on Assets (%) 1.85
Return on Capital (%) 2.61
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.79
Total Assets 142.83
Total Liabilities 142.83
Total Equity 120.47
Share Outstanding 15434190
Price to Book Ratio 0.83
Return on Assets (%) 0.58
Return on Capital (%) 0.63
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 18.62
Total Assets 287.47
Total Liabilities 287.47
Total Equity 222.92
Share Outstanding 16082319
Price to Book Ratio 2.81
Return on Assets (%) 6.11
Return on Capital (%) 6.91
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 17.96
Total Assets 252.41
Total Liabilities 252.41
Total Equity 195.93
Share Outstanding 15582319
Price to Book Ratio 1.14
Return on Assets (%) 6.22
Return on Capital (%) 7.22
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.44
Total Assets 232.29
Total Liabilities 232.29
Total Equity 178.03
Share Outstanding 15582129
Price to Book Ratio 1.49
Return on Assets (%) 4.53
Return on Capital (%) 5.31
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 5.77
Total Assets 195.84
Total Liabilities 195.84
Total Equity 162.93
Share Outstanding 15494544
Price to Book Ratio 0.77
Return on Assets (%) 3.14
Return on Capital (%) 3.47
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.72
Total Assets 174.11
Total Liabilities 174.11
Total Equity 151.64
Share Outstanding 15434190
Price to Book Ratio 0.83
Return on Assets (%) 2.55
Return on Capital (%) 2.72
Particulars MAR 2024 (Values in Cr)
Net Income 19.35
Cash from Operations 6.88
Cash from Investing -9.54
Cash from Financing 8.80
Net change in Cash -0.88
Free Cash Flow 13.33
Particulars MAR 2023 (Values in Cr)
Net Income 12.01
Cash from Operations 6.91
Cash from Investing 7.91
Cash from Financing -0.71
Net change in Cash 9.78
Free Cash Flow 10.72
Particulars MAR 2022 (Values in Cr)
Net Income 9.61
Cash from Operations 8.31
Cash from Investing -15.25
Cash from Financing 7.02
Net change in Cash -2.43
Free Cash Flow 16.52
Particulars MAR 2021 (Values in Cr)
Net Income 5.11
Cash from Operations 46.67
Cash from Investing -37.56
Cash from Financing 1.61
Net change in Cash 9.70
Free Cash Flow 82.96
Particulars MAR 2020 (Values in Cr)
Net Income 1.60
Cash from Operations 6.71
Cash from Investing -10.45
Cash from Financing 0.84
Net change in Cash -5.14
Free Cash Flow 17.21
Particulars MAR 2024 (Values in Cr)
Net Income 23.35
Cash from Operations -4.15
Cash from Investing -10.09
Cash from Financing 11.40
Net change in Cash -9.88
Free Cash Flow 2.36
Particulars MAR 2023 (Values in Cr)
Net Income 19.44
Cash from Operations 10.42
Cash from Investing 6.24
Cash from Financing 3.04
Net change in Cash 15.38
Free Cash Flow 13.97
Particulars MAR 2022 (Values in Cr)
Net Income 13.92
Cash from Operations 7.74
Cash from Investing -16.08
Cash from Financing 7.55
Net change in Cash -3.32
Free Cash Flow 15.94
Particulars MAR 2021 (Values in Cr)
Net Income 7.50
Cash from Operations 7.13
Cash from Investing -5.34
Cash from Financing 2.27
Net change in Cash 3.05
Free Cash Flow 7.55
Particulars MAR 2020 (Values in Cr)
Net Income 5.22
Cash from Operations 9.53
Cash from Investing -10.08
Cash from Financing 1.44
Net change in Cash -1.34
Free Cash Flow 10.54
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 65.90 37.87 3.59 505.01 37.54 / 77.70
BLISS GVS PHARMA LTD 155.50 19.46 1.62 1637.91 92.25 / 172.40
CIPLA LTD 1455.65 25.47 4.14 117560.12 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 414.95 144.08 4.20 1221.24 145.00 / 440.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 65.90 57.30 11.20 505.01 37.54 / 77.70
AMRUTAJAN HEALTH LTD 753.60 45.84 7.31 2178.71 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6634.15 128.84 24.41 16585.38 4050.15 / 8139.85
BLISS GVS PHARMA LTD 155.50 20.27 1.59 1637.91 92.25 / 172.40

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 330.50
  • 26 Days 320.60
  • 10 Days 325.40
  • 50 Days 326.00
  • 12 Days 324.20
  • 100 Days 330.20
  • 20 Days 320.00
  • 200 Days 404.00
326.92
PIVOT
First Resistance 331.73
Second Resistance 338.67
Third Resistance 343.48
First Support 319.98
Second Support 315.17
Third Support 308.23
RSI 52.19
MACD 3.57
Commodity Channel Index (CCI) 43.22
ADX 22.24
Williams % R -51.42

Over 1 Month

down

7.63

Over 3 Months

down

-13.72

Over 6 Months

down

-1.14

Over 1 Year

down

-5.20

Over 3 Years

down

23.77

Over 5 Years

down

22.80

KILITCH DRUGS INDIA LTD Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

KILITCH DRUGS INDIA LTD Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
30.76
Promoter Holdings
69.23
FII
0.0
DII
0.0
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Kilitch Company (pharma) Limited Shareholding of Promoter and Promoter Group 6629342.0 41.22
Bhavin Mukund Mehta Shareholding of Promoter and Promoter Group 2523138.0 15.69
Mukund Mehta Shareholding of Promoter and Promoter Group 1140647.0 7.09
Mira Bhavin Mehta Shareholding of Promoter and Promoter Group 841046.0 5.23
Dipak Kanayalal Shah Public Shareholding 500000.0 3.11
Sherni Shares Limited Public Shareholding 219751.0 1.37

KILITCH DRUGS INDIA LTD

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2019-09-20 0.5 Final 2019-09-24 Equity shares 2018-09-18 0.5 Final 2018-09-20 Equity shares 2012-09-24 30.0 Special 2012-09-25 Equity shares 2011-08-18 1.0 Final 2011-08-23 Equity shares 2010-10-14 1.0 Final 2010-10-15 Equity shares 2009-09-10 1.0 Final 2009-09-12 Equity shares 2008-09-10 1.0 Final 2008-09-12 Equity shares 2007-11-15 1.0 Interim 2007-11-16 Equity shares
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About KILITCH DRUGS INDIA LTD

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by KILITCH DRUGS INDIA LTD

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Kilitch Drugs (India) Ltd?

Answer Field

The share price of Kilitch Drugs (India) Ltd for NSE is ₹ 326.5 and for BSE is ₹ 327.35.

What is the Market Cap of Kilitch Drugs (India) Ltd?

Answer Field

The market cap of Kilitch Drugs (India) Ltd for NSE is ₹ 5,25.08 Cr. and for BSE is ₹ 5,26.45 Cr. as of now.

What is the 52 Week High and Low of Kilitch Drugs (India) Ltd?

Answer Field

The 52 Week High and Low of Kilitch Drugs (India) Ltd for NSE is ₹ 470.00 and ₹ 300.00 and for BSE is ₹ 469.85 and ₹ 298.45.

How to Buy Kilitch Drugs (India) Ltd share?

Answer Field

You can trade in Kilitch Drugs (India) Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Kilitch Drugs (India) Ltd?

Answer Field

The 1 year returns on the stock has been -5.20%.

What is the Current Share Price of Kilitch Drugs (India) Ltd?

Answer Field

Kilitch Drugs (India) Ltd share price is for NSE ₹ 326.5 & for BSE ₹ 327.35 as on Dec 11 2024 03:29 PM.

What is the Market Cap of Kilitch Drugs (India) Ltd Share?

Answer Field

The market cap of Kilitch Drugs (India) Ltd for NSE ₹ 5,25.08 & for BSE ₹ 5,26.45 as on Dec 11 2024 03:29 PM.

What is the P/E Ratio of Kilitch Drugs (India) Ltd Share?

Answer Field

As on Dec 11 2024 03:29 PM the price-to-earnings (PE) ratio for Kilitch Drugs (India) Ltd share is 23.87.

What is the PB ratio of Kilitch Drugs (India) Ltd Share?

Answer Field

As on Dec 11 2024 03:29 PM, the price-to-book (PB) ratio for Kilitch Drugs (India) Ltd share is 147.27.

How to Buy Kilitch Drugs (India) Ltd Share?

Answer Field

You can trade in Kilitch Drugs (India) Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Kilitch Drugs (India) Ltd Share on Bajaj Broking App?

Answer Field

To buy Kilitch Drugs (India) Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Kilitch Drugs (India) Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader